Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria
Go back to Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 16.90 -0.95 (5.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.85 | 52 Week High | $19.75 | |||
| Open | $18.40 | 52 Week Low | $4.26 | |||
| Day High | $18.42 | P/E | N/A | |||
| Day Low | $16.64 | EPS | $0.00 | |||
| Volume | 5,780,327 | |||||
